Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2/β-catenin pathway

As a common malignant tumor among women, ovarian cancer poses a serious threat to their health. This study demonstrates that long non-coding RNA NRSN2-AS1 is over-expressed in ovarian cancer tissues using patient sample and tissue microarrays. In addition, NRSN2-AS1 is shown to promote ovarian cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Bo, Li, Shen-Yi, Liu, Jin-Yan, Xue, Jia-Jia, Xu, Jin-Fu, Chen, Ting, Cao, Tian-Yue, Zhou, Hui, Wu, Tian-Tian, Dong, Chun-Lin, Qian, Wei-Feng, Qiao, Long-Wei, Hou, Shun-Yu, Wang, Ting, Shen, Cong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598275/
https://www.ncbi.nlm.nih.gov/pubmed/37875515
http://dx.doi.org/10.1038/s41419-023-06214-z
Descripción
Sumario:As a common malignant tumor among women, ovarian cancer poses a serious threat to their health. This study demonstrates that long non-coding RNA NRSN2-AS1 is over-expressed in ovarian cancer tissues using patient sample and tissue microarrays. In addition, NRSN2-AS1 is shown to promote ovarian cancer cell proliferation and metastasis both in vitro and in vivo. Mechanistically, NRSN2-AS1 stabilizes protein tyrosine kinase 2 (PTK2) to activate the β-catenin pathway via repressing MG-53-mediated ubiquitinated degradation of PTK2, thereby facilitating ovarian cancer progression. Rescue experiments verify the function of the NRSN2-AS1/PTK2/β-catenin axis and the effects of MG53 on this axis in ovarian cancer cells. In conclusion, this study demonstrates the key role of the NRSN2-AS1/PTK2/β-catenin axis for the first time and explores its potential clinical applications in ovarian cancer.

Ejemplares similares